Clinical Trial Update: Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) [Phase 2, Phase 3]

View source ↗

Summary

Three-year follow-up results from a trial comparing boceprevir and narlaprevir in chronic hepatitis C were reported after termination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• Narlaprevir (narlaprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic, Hepacivirus | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2015-10-06